Searchable abstracts of presentations at key conferences in endocrinology

ea0077op1.2 | Thyroid | SFEBES2021

Long term Management of Thyrotoxicosis with Anti thyroid Drugs (ATDs)

Shaikh Ayesha , Saraf Asish , Udiawar Maneesh , Boregowda Kusuma , Price David

Background: Recent NICE guidance recommends radioactive iodine as the first line treatment for relapsed thyrotoxicosis as it reportedly produces better control than long-term anti-thyroid drugs (ATDs).However, almost all studies of long-term ATDs relapse occurs after discontinuation of a medication. We present a retrospective analysis of efficacy of ATDs. Methods: Data of all patients with hyperthyroidism, attending Endocrinology clinic at Morriston Hosp...

ea0077op1.3 | Thyroid | SFEBES2021

Thyroid Endocrine Nurse Service: Improving patient experience

Choa Dri , Khan Shaila , Beauge Amandine , Gable David , Agha-Jaffar Rochan , Robinson Stephen

Aims: Within Imperial College Healthcare Trust, St Mary’s Hospital has a large one-stop shop thyroid service. On average, 700 encounters have been recorded per annum in the St Mary’s thyroid nurse-led service since its inception in June 2017. We aimed to critically evaluate the role of the specialist nurse within safe and robust monitoring clinical parameters, to determine the conditions managed in the nurse-led service and assess attendance rate.<p class="abstex...

ea0077op1.4 | Thyroid | SFEBES2021

Autoimmune thyrotoxicosis: Is first line treatment with anti-thyroid medication good enough?

Pooley George , Shishkin Bronwyn , DeSilva Akila

Introduction: Autoimmune thyrotoxicosis (AT) affects 2-5% of the Western population. Despite current NICE guidelines recommending radioiodine as first-line treatment for AT, practical considerations such as licensing often prevent this. Typically, anti-thyroid medication (carbimazole or propylthiouracil) is initially offered. Patients are usually counselled that the remission rate following a 12-18 month course of anti-thyroid medication is approximately 50%.<p class="abst...

ea0077op2.1 | Adrenal and Cardiovascular | SFEBES2021

A phase 1 clinical trial evaluating the safety and efficacy of up to two administrations of the adrenal PET tracer [18F]CETO in healthy volunteers and patients with primary aldosteronism

Senanayake Russell , Gillett Daniel , Bashari Waiel , MacFarlane James , Hu Lihua , Palma August , Aloj Luigi , Mendichovszky Iosif , Hader Stefan , Boros Istvan , Brown Morris , Cheow Heok , Aigbirhio Franklin , Gurnell Mark

Background: Primary aldosteronism (PA) is an important, potentially curable, cause of hypertension. Distinguishing unilateral and bilateral causes is a critical step in determining who should be considered for adrenalectomy. Adrenal vein sampling (AVS) remains the gold standard for lateralisation. However, AVS is technically challenging with limited availability. To address this, we have introduced molecular imaging using PET/CT with the radiotracer [11C]Metomidate ...

ea0077op2.2 | Adrenal and Cardiovascular | SFEBES2021

Single-centre analysis of 900 short synacthen tests: do pre-test clinical or biochemical variables predict failure?

Dilrukshi M D S A , Beck K J , Loo H , May C , Jafar-Mohammadi B , Pofi R , Tomlinson J W , Pal A

Short synacthen test (SST) is the most widely used dynamic test of hypothalamic-pituitary-adrenal (HPA) axis function. It’s simple to conduct but requires nursing time and is relatively costly given 15-fold price increase in synacthen since 2015. We audited our SST use with the aim of reviewing clinical indications for testing and identifying useful predictors of test outcome. Baseline referral, clinical and biochemical data were retrospectively collected for individuals ...

ea0077op2.3 | Adrenal and Cardiovascular | SFEBES2021

PLK1 inhibitors as a new targeted treatment for adrenocortical carcinoma

Warmington Emily , Smith Gabrielle , Chortis Vasileios , Khan Sana , Lippert Juliane , Hantel Constanze , Liang Raimunde , Kiseljak-Vassiliades Katja , Wierman Margaret , Altieri Barbara , Fassnacht Martin , Foster Paul , Ronchi Cristina

Adrenocortical carcinoma (ACC) is an aggressive malignancy with limited treatment options. We identified polo-like kinase 1 (PLK1) as one of the most overexpressed genes and potential drug target in ACC. PLK1 inhibitors (PLK1i) are under evaluation in clinical trials for other malignancies, being more effective in TP53-mutated tumours. Here we test PLK1i efficacy in four ACC cell lines with different genetic background. Efficacy of three PLK1i (i.e. Volaserti...

ea0077op2.4 | Adrenal and Cardiovascular | SFEBES2021

Modelling changes in the control, secretion and metabolism of cortisol during and after heart surgery

Galvis Daniel , Zavala Eder , Walker Jamie , Upton Thomas , Lightman Stafford , Angelini Gianni , Gibbison Ben

Control mechanisms of adrenocorticotrophic hormone (ACTH) and cortisol (CORT) secretion and metabolism during acute systemic inflammation (e.g. major surgery) have never been clearly elucidated. We sampled blood every 10 minutes for 12 h during and after coronary artery bypass grafting (CABG) in 10 patients to create profiles of ACTH, CORT and inflammatory mediators and compared these to healthy controls. Patients’ ACTH and CORT responses were classified into one of three...

ea0077op3.1 | Reproductive and Neuroendocrinology | SFEBES2021

Discordant growth hormone and insulin like growth factor-1 values are associated with an increased mortality over concordant normal values in patients treated for acromegaly

Abeyaratne Dayakshi , Kaniuka-Jakubowska Sonia , Plummer Zoe , Archer Natasha , Lakmal Fonseka Chathuranga , Ayuk John , Peter James , McNally Richard , Michael Orme Stephen , Rees Aled , Pal Aparna , Wass John

Background: Growth hormone (GH) and Insulin like growth factor 1 (IGF-1) discordance in patients with acromegaly is a well-recognised phenomenon. It is unclear whether this is associated with increased mortality and morbidity compared to patients with concordant normal results.Methodology: A retrospective study was conducted on the United Kingdom Acromegaly Registry (UKAR). A comparison of mortality and morbidity was performed among four groups categoris...

ea0077op3.2 | Reproductive and Neuroendocrinology | SFEBES2021

An ex-vivo human placental model demonstrates that temporal fluctuations in maternal glucose in gestational diabetes alter placental transcriptome networks associated vascular development and angiogenesis

Byford Abigail , Walsh Katy , Scott Eleanor , Forbes Karen

Aims: Women with gestational diabetes (GDM) who deliver large-for-gestational age (LGA) infants have subtle (1-1.5mM) differences in temporal maternal glucose control detectable by continuous glucose monitoring (CGM), compared to women who deliver appropriate-for-gestational-age (AGA) infants. It is unclear how these subtle changes cause LGA, but LGA has been linked to placental dysfunction. We aimed to develop an ex-vivo human placental model to mimic subtle differences in te...

ea0077op3.3 | Reproductive and Neuroendocrinology | SFEBES2021

‘Suppression imaging’ – a novel PET technique for increasing confidence in the localisation of secretory pituitary microadenomas

MacFarlane James , Kourlouri Olympia , Gillett Daniel , Senanayake Russell , Santarius Thomas , Tysome James , Donnelly Neil , Mendichovszky Iosif , Cheow Heok , Mannion Richard , Bashari Waiel , Gurnell Mark

Background: In a sub-group of patients with newly diagnosed pituitary adenomas, conventional MRI will fail to confidently localise the tumour. The role of molecular imaging for these patients is increasingly being recognised, both in terms of confirming diagnosis and in guiding targeted therapy; 11C-Methionine PET co-registered with volumetric MRI (Met-PET/MRCR) can enhance decision making in this group of patients. However, in some cases distinguishing t...